Non Muscle Invasive Bladder Cancer Market Worth US$ 5.5 billion by 2031 – Growth Plus Reports

Newark, New Castle, USA, July 06, 2023 (GLOBE NEWSWIRE) — The market analysis of the global non muscle invasive bladder cancer market was conducted by Growth Plus Reports in 2022 and was valued at US$ 2.9 billion. The market is expected to hit a revenue CAGR of 6.5% to reach US$ 5.5 billion by 2031.

Analysis of the global market for non muscle invasive bladder cancer indicates that during the forecast period, revenue share is likely to increase significantly. The bladder muscle is not affected by non-muscle invasive bladder cancer, which grows in the bladder lining. Among all malignancies in the US, bladder cancer is the sixth most common.

Key Takeaways: 

• The increasing number of patients with bladder cancer is driving the market revenue share.
• The rising demand for immunotherapies and chemotherapy for cancer cure is driving the market demand.
• The rising population smoking cigarettes is increasing the market revenue growth rapidly.

Download Free Sample Report Now @ https://www.growthplusreports.com/inquiry/request-sample/non-muscle-invasive-bladder-cancer-market/8327

                     Non Muscle Invasive Bladder Cancer Market Scope

Recent Development in the Non muscle invasive bladder cancer Market: 

• In November 2021, In combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) that is resistant to Bacillus Calmette-Guerin (BCG), the preliminary Phase II trial (CORE1) findings for CG0070 were reported. The combination of CG0070 and pembrolizumab was well tolerated in 9 individuals and showed promising early effectiveness results.

Competitive Landscape

A list of the companies operating in the global market for non muscle invasive bladder cancer includes: 

• Sun Pharmaceutical Industries, Inc.
• Pfizer Inc.
• Ferring B.V.
• AstraZeneca
• Merck & Co., Inc.
• Lilly USA, LLC

Market Drivers and Restraints: 

The global non muscle invasive bladder cancer market revenue is driven by the prevalence of bladder cancer, preventive measures taken by the population due to rising awareness, and advancements in technology for early diagnosis and cancer detection. 

However, due to the expensive treatments and regulatory measures for several treatment options, the non muscle invasive bladder cancer market revenue growth is expected to be restrained. 

Market Segmentation: 

Segmentation By Treatment Type

Based on the treatment types, the chemotherapy segment dominates the global non muscle invasive bladder cancer market with the largest revenue share. This sizable share of revenue is attributed to its high demand. Immunotherapy is the fastest-growing segment in which Bacillus Calmette-Guérin (BCG) and pembrolizumab are potential treatment options. 

Segmentation By End User 

Based on end-user, the hospital segment accounts for the highest revenue share in the global non muscle invasive bladder cancer market due to the growing number of bladder cancer patients with a requirement for treatment. 

Request for Customization – https://www.growthplusreports.com/inquiry/customization/non-muscle-invasive-bladder-cancer-market/8327

Regional Growth Dynamics

Based on the region, North America, with the largest revenue share, dominates the global non muscle invasive bladder cancer market. This sizable share of revenue is attributed to the need for non-muscle invasive bladder cancer therapies is growing in North America as bladder cancer incidence rates rise.

Report Coverage 

Global market research on the non muscle invasive bladder cancer market was done in-depth by Growth Plus Reports. We looked at the core market traits, noteworthy investment prospects, regional growth trends, ten-year revenue projections, rival market participants, and mergers and acquisitions.

Table of Content

1. INTRODUCTION
   1. Market Ecosystem 
   2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Years – 2022
      3. Forecast Years – 2023 to 2031
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up 
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions       
3. PREMIUM INSIGHTS
   1. Current Market Trend (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2022) 
   3. Regulatory Landscape
   4. Reimbursement Scenario
   5. Epidemiology & Patient Population
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL NON MUSCLE INVASIVE BLADDER CANCER MARKET ANALYSIS & FORECAST, BY TREATMENT TYPE 
   1. Chemotherapy 
   2. Immunotherapy 
   3. Targeted Therapy 
6. GLOBAL NON MUSCLE INVASIVE BLADDER CANCER MARKET ANALYSIS & FORECAST, BY END USER 
   1. Hospital 
   2. Cancer Specialty Centers 
   3. Others (Ambulatory Care Centers, Clinics)

NON MUSCLE INVASIVE BLADDER CANCER MARKET TOC

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8327

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at – https://www.growthplusreports.com/report-store

Browse more latest healthcare reports:

Subcutaneous Immunoglobulin (SCIg) Therapy Market by Indication (Primary Immunodeficiency Disease, Chronic Inflammatory Demyelinating Polyneuropathy), Distribution Channel (Hospital Pharmacies, Online Pharmacies) – Global Outlook & Forecast 2023-2031

Acute Flaccid Myelitis Market by Treatment Type (Pharmacological Treatment, Physical & Occupational Therapy, Plasmapheresis, and Others) – Global Outlook & Forecast 2023-2031

Cell & Gene Therapy Clinical Trials Market by Phase (Phase I, Phase II), Indication (Oncology, Cardiology) – Global Outlook & Forecast 2023-2031

Cementless Total Knee Arthroplasty Market by Product Type (Fixed Bearing, Mobile Bearing), By End User (Hospitals, Specialty Surgical Centers) – Global Outlook and Forecast 2023-2031

Dermatology Endoscopy Devices Market by Product (Non-Polarized, Polarized), Type (Digital Dermato-scopes, Traditional/Analogue Dermato-scopes), Modality (Trolley-mounted, Handheld), Application (Scabies, Skin Cancer) – Global Outlook & Forecast 2023-2031

Unleashing the Power of Innovation in Med Tech:  https://growthplusmedtechroundup.com

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020”.